Clinical trials: Advanced or Metastatic Solid Tumors
Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumors that…
- Conditions
- Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma
- Trial name
- FOCUS-01 (NCT07454642)
- Testing
- AVA6103
- Where
- 7 sites in United States
- Volunteers
- 174 people
- Sponsor
- Avacta Life Sciences Ltd
Neoplasm
Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)
This clinical study evaluates the safety, tolerability, pharmacokinetics, and immunogenicity of dalotuzumab (MK-0646) in participants with relapsed or refractory locally advanced or metastatic solid tumors using once weekly and…
- Trial name
- NCT00694356
- Testing
- Dalotuzumab
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC
Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors
This is a phase 1, multicenter, open-label, single-arm study to investigate the safety and tolerability of encorafenib 300 mg once daily (QD) monotherapy in adult Chinese participants with B-RAF Proto-oncogene, Serine/threonine…
- Conditions
- BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma
- Trial name
- OCEANI (NCT05003622)
- Testing
- Encorafenib
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Pierre Fabre Medicament
Solid Tumors
CetuGEX™: Phase 1 Study in Cancer Patients
This was a prospective, open label, multicenter study evaluating the safety, tolerability and pharmacokinetics of CetuGEX™ after intravenous administration in patients with EGFR positive, locally advanced and/or metastatic solid…
- Trial name
- NCT01222637
- Testing
- CetuGEX™
- Where
- 5 sites in Germany, Italy and 1 more
- Volunteers
- 41 people
- Sponsor
- Glycotope GmbH
Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer.
- Conditions
- Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer
- Trial name
- NCT07510802
- Testing
- Dual-target CAR-NK cells, Lymphodepleting, Supportive care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Advanced or Metastatic Solid Tumor Malignancies
A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) level(s) of GIGA-564 in participants with metastatic or locally…
- Trial name
- NCT06258304
- Testing
- GIGA-564
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- GigaGen, Inc.
Solid Cancers
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
This is a two stage, Phase Ib study designed to describe the pharmacokinetics of GDC-0449 in patients with advanced solid tumors that are refractory to treatment or for whom no standard therapy exists.
- Trial name
- NCT00968981
- Testing
- GDC-0449
- Volunteers
- 67 people
- Sponsor
- Genentech, Inc.
Urothelial Carcinoma, Bladder Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy…
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult, Chemotherapy-induced Neutropenia
- Trial name
- PRESERVE3 (NCT04887831)
- Testing
- Trilaciclib, Gemcitabine, Cisplatin
- Where
- 34 sites in United States, France and 3 more
- Volunteers
- 92 people
- Sponsor
- G1 Therapeutics, Inc.
Breast Cancer, Glioblastoma
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
This is a Phase 1 dose-escalation study of PRT3645, a Cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor, in patients with advanced or metastatic solid tumors.
- Conditions
- Breast Cancer, Glioblastoma, Head and Neck Squamous Cell Carcinoma, Malignant Mesothelioma
- Trial name
- NCT05538572
- Testing
- PRT3645
- Where
- 13 sites in United States, Singapore
- Volunteers
- 22 people
- Sponsor
- Prelude Therapeutics Incorporated
Advanced Solid Tumors, Metastatic Solid Tumors
Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
The purpose of this first-in-human (FiH) study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of CKD-512 given alone and in combination with pembrolizumab in subjects…
- Trial name
- NCT07215637
- Testing
- CKD-512, Pembrolizumab
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Advanced Solid Tumor
JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors
This study is an open-label, multicenter, first-in-human, Phase I/II (dose escalation and dose expansion) study to evaluate the safety, tolerability, PK, immunogenicity and efficacy of JSKN033 in patients with advanced…
- Trial name
- NCT06226766
- Testing
- JSKN033 Injection
- Where
- Australia
- Volunteers
- 11 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Solid Tumor
Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
To evaluate the safety and tolerability of IBI3005 combination therapy in participants with advanced solid tumors; to evaluate the antitumor activity of IBI3005 combination therapy in participants with advanced solid tumors.
- Trial name
- NCT07612137
- Testing
- IBI3005, Sintilimab, Bevacizumab biosimilar
- Where
- China
- Volunteers
- 282 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Non-small Cell Lung Cancer, Solid Tumor
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
This study is an open-label, multicenter, dose-escalation and cohort-expansion, non-randomized Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M09D1 for…
- Trial name
- NCT07056556
- Testing
- BL-M09D1
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Ovarian Cancer, Small Cell Lung Cancer
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C…
- Conditions
- Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT07752875
- Testing
- LG00313112
- Volunteers
- 250 people
- Sponsor
- LG Chem
Solid Tumor
Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors
SYD985.004 is a two-part phase I study with the antibody-drug conjugate SYD985 in combination with niraparib aimed at evaluating safety, pharmacokinetics and efficacy in patients with HER2-expressing locally advanced or…
- Trial name
- NCT04235101
- Testing
- SYD985 + Niraparib
- Where
- 6 sites in Belgium, Netherlands and 1 more
- Volunteers
- 32 people
- Sponsor
- Byondis B.V.
Advanced Solid Tumors
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer
This is an open-label study, in participants with advanced and/or metastatic solid tumors, which consists of 2 parts: a research phase (inpatient) and a treatment phase.
- Trial name
- NCT03991494
- Testing
- [14C]-pamiparib
- Where
- 2 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- BeiGene
Solid Tumor, Breast Cancer
Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy
To determine the Maximally Tolerable Dose (MTD) of KOS-1022 when administered weekly in combination with trastuzumab or in combination with trastuzumab and paclitaxel to patients with advanced solid tumor malignancies
- Trial name
- NCT00803556
- Testing
- Alvespimycin, Trastuzumab, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumors
Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16
This is an open, multi-center, multi-cohort phase I clinical study designed to evaluate safety, tolerability, pharmacokinetics and initial efficacy of FTL008.16 in patients with advanced and metastatic solid tumors.
- Trial name
- NCT06410131
- Testing
- FTL008.16
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Sound Biopharmaceuticals Ltd.
Neoplasms Malignant
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104
This was a first-in-human, Phase 1 study designed to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK117 as monotherapy or in combination with AK104 in subjects…
- Trial name
- NCT04349969
- Testing
- AK117, AK117+AK104
- Where
- 4 sites in Australia
- Volunteers
- 38 people
- Sponsor
- Akesobio Australia Pty Ltd
NTRK Family Gene Mutation
Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion
The objective of this registry is to analyze treatment reality and outcome of patients with locally advanced or metastatic solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3
- Trial name
- REALTRK (NCT04557813)
- Where
- 26 sites in Germany, Switzerland
- Volunteers
- 88 people
- Sponsor
- iOMEDICO AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.